Post-study treatment does not influence outcome in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
- Borner, M.
- Cassidy, J.
- Cervantes, A.
- Koralewski, P.
- Zaluski, J.
- Schuller, J.
- Husseini, F.
- Teller, S.
- Twelves, C.
ISSN: 1359-6349
Year of publication: 2005
Volume: 3
Issue: 2
Pages: 179-179
Type: Conference paper